Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine PR for myotonia in myotonic dystrophy type 1 and type 2
2024-511179-13-00Phase 3Authorised
- Sponsor
- Lupin Limited
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) comparing Mexiletine PR with Placebo (2 arms). Primary endpoint: Handgrip relaxation time in DM1 patients. Planned start Jan 2025; status: authorised.
02
Drugs
mexiletine
03
Conditions
myotonic dystrophy type 1 (DM1)myotonic dystrophy type 2 (DM2)
Beyond the preview
Go deeper on 2024-511179-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511179-13-00.